Flexibility to help you meet your patients’ needs1


AJOVY is the only approved anti-CGRP preventive migraine treatment with quarterly and monthly dosing options


675 mg (225 mg x 3) SQ

Only 4 injection days per year



225 mg SQ

Only 1 injection per month


In office

by a healthcare professional


At home

by patient or caregiver

Guidance on proper subcutaneous administration techniques should be provided.


Alone and in combination with oral preventive treatments

  • 1000+ patients received AJOVY as a stand-alone preventive treatment
  • 280+ patients continued to receive their oral preventive treatment


Real-world patients

  • Phase 3 trials enrolled nearly 600 patients that had discontinued prior preventive treatment2

  • 18% of women of childbearing age also took concomitant hormonal contraceptives2

There are no adequate data on the developmental risk associated with the use of AJOVY in pregnant women. AJOVY has a long half-life. This should be taken into consideration for women who are pregnant or plan to become pregnant while using AJOVY.1


CGRP: calcitonin gene-related peptide; SQ: subcutaneous.

Suggestions to explore next

Continue to AJOVY Efficacy page

AJOVY helped significantly reduce monthly migraine days vs placebo1

see the clinical trial data for ajovy

Savings Offer for AJOVY

Download Savings Offer

AJOVY is a monoclonal antibody that selectively targets the CGRP ligand1

see how ajovy works